First Commercial Bulk Sale
Dyadic International achieved its first commercial bulk sale of a Dyadic-produced protein, marking a pivotal transition from a platform-centric R&D organization to a commercially focused biotechnology company.
Rebranding and Website Relaunch
The company rebranded as Dyadic Applied Biosolutions and launched a redesigned corporate website to enhance commercial engagement.
CRISPR Cas9 Gene Editing License
Dyadic obtained a license for CRISPR Cas9 gene editing capabilities, enhancing strain optimization and productivity, which supports commercialization and profitability.
Milestone Payments from ProLiant
Dyadic received a total of $1.5 million in milestone payments from ProLiant, including a third payment of $500,000 in October, signifying progress in the recombinant human albumin program.
Partnership with Intralink
Dyadic partnered with Intralink to accelerate market penetration in Japan and South Korea, expanding their global market reach efficiently.